| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $59 price target.
Cantor Fitzgerald analyst Jennifer Kim reiterates Belite Bio (NASDAQ:BLTE) with a Overweight.
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.28) by...
Additional analysis of visual acuity loss, genotypic profiles, and retinal imaging data from a 24-month Phase 2 trial of Tinlar...
Belite Bio entered into a securities purchase agreement with an institutional investor, for the purchase and sale of up to an a...
HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and maintains $59 price target.
Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug developm...
HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $59 price target.
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.30) by...
